1. Market Research
  2. > Pharmaceutical
  3. > Drug Development Market Trends
Market Spotlight: Mesothelioma, Pharma Intelligence

Market Spotlight: Mesothelioma, Pharma Intelligence

  • October 2019
  • 40 pages
  • ID: 5780124
  • Format: PDF
  • By Pharma Intelligence

Summary

Table of Contents

Mesothelioma is an aggressive and rare form of cancer which develops in the lining of the heart, lungs, or abdomen. Exposure to asbestos is the primary cause of the disease. The inhalation or swallowing of asbestos leads to an accumulation in the lining of the lungs or the abdomen, causing damage to the tissue. This, in turn, leads to damage to the cells’ DNA, and uncontrolled cell growth.

Key Takeaways
The analyst estimates that in 2017, there were 18,900 incident cases of mesothelioma in adults aged 45 years and older worldwide, and forecasts that number to increase to 22,690 incident cases by 2026.
Oceania is estimated to have the highest disease incidence (2.85 per 100,000 males, and 0.50 per 100,000 females), while Latin America and the Caribbean has the lowest incidence (0.29 per 100,000 males, and 0.17 per 100,000 females).
The approved drugs in the mesothelioma space target thymidylate synthase, the immune system, programmed death-1 receptor/programmed death ligands, and dihydrofolate reductase. All of the approved drugs are administered via the intravenous route.
The majority of industry-sponsored drugs in active clinical development for mesothelioma are in Phase II. Therapies in the mesothelioma space focus on a wide variety of targets. The majority of drugs in development for mesothelioma are administered via the intravenous route, with the remainder being intramuscular, oral, intratumoral, percutaneous catheter/injection, and subcutaneous formulations.
The only high-impact upcoming event for drugs in the mesothelioma space is topline Phase II trial results for Zepsyre. The overall likelihood of approval of a Phase I mesothelioma asset is 6.3%, and the average probability a drug advances from Phase III is 33.3%. Drugs, on average, take 14.8 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
There have been seven licensing and asset acquisition deals involving mesothelioma drugs during 2014–19. The $475m licensing agreement signed in 2017 between Calithera Biosciences and Incyte to research, develop, and commercialize Calithera’s CB-1158 was the largest deal.
The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials have been in the early and mid-phases of development, with 95% of trials in Phase I–II, and only 5% in Phase III–IV.
The US has a substantial lead in the number of mesothelioma clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
Clinical trial activity in the mesothelioma space is dominated by completed trials. Eli Lilly has the highest number of completed clinical trials for mesothelioma, with 44 trials. Eli Lilly also leads industry sponsors with the highest overall number of clinical trials for mesothelioma.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019

Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019SummaryTumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Recepto ...

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019SummaryWilms Tumor Protein (WT33 or WT1) pipeline Target constitutes close to 16 molecules. Out of which approximately 8 molecules are developed ...

Tumor Necrosis Factor Receptor Superfamily Member 9 - Pipeline Review, H2 2019

Tumor Necrosis Factor Receptor Superfamily Member 9 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Tumor Necrosis Factor Receptor Superfamily Member 9 - Pipeline Review, H2 2019SummaryTumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on